PharmEasy is a company.
PharmEasy has raised $323.0M across 5 funding rounds.
Key people at PharmEasy.
PharmEasy has raised $323.0M in total across 5 funding rounds.
Key people at PharmEasy.
PharmEasy has raised $323.0M in total across 5 funding rounds.
PharmEasy's investors include Bessemer Venture Partners, Fundamentum, Prime Venture Partners.
PharmEasy is India's leading online healthcare aggregator, connecting patients with local pharmacies and diagnostic centers for medicine delivery, lab tests, and teleconsultations.[1][2][3] Founded in 2015, it serves over 20 million customers across 1,200+ cities and 22,000+ pin codes, offering an asset-light model that partners with 60,000+ brick-and-mortar pharmacies instead of holding inventory, solving accessibility and affordability issues in India's fragmented healthcare system.[1][2][4] With ₹10,031 Cr in total funding and key backers like Temasek and Prosus, it has grown through acquisitions like Medlife (2021) and Thyrocare (66.1% stake for ₹4,546 Cr), while providing PharmEasy Plus memberships for cashback, free delivery, and doctor consultations.[1][2][5]
The platform addresses key pain points like medicine availability, high costs, and inconvenient access by enabling quick orders via mobile apps, home sample collection for tests, and commissions from diagnostics and pharmacy partnerships, achieving rapid scale with 3,689 employees as a public limited company.[1][3][4]
PharmEasy was founded in 2015 in Mumbai by Dharmil Sheth and Dr. Dhaval Shah, who bootstrapped with seed funding from their parents to tackle healthcare inaccessibility.[2][5] Sheth, with e-commerce experience, and Shah, a doctor, launched as a medicine delivery app amid India's challenges with pharmacy access and counterfeit drugs, emphasizing transparency and trust.[2]
Early traction came from expanding beyond Mumbai via Series A funding, evolving into a full aggregator for pharmacies and diagnostics.[1][5] Pivotal moments included the 2021 Medlife acquisition to consolidate market share and the Thyrocare deal—India's first unicorn buyout of a listed firm—plus Aknamed for supply chain strength, pushing valuation to $5.6B after a $350M pre-IPO round.[2][5] Despite filing for a ₹6,250 Cr IPO in 2021, it withdrew in 2022 amid market conditions.[5]
PharmEasy stands out in India's e-pharmacy space through these key strengths:
PharmEasy rides India's digital health boom, fueled by smartphone penetration (over 800M users), rising chronic diseases, and post-COVID demand for contactless care, timing perfectly with e-pharmacy regulations easing online sales.[2][5] Market forces like urban-rural healthcare gaps (only 20% access diagnostics easily) and a $100B+ pharma retail sector favor its aggregator approach, enabling 20M+ users while competitors like Reliance's Netmeds or Tata's 1mg consolidate.[2][5]
It influences the ecosystem by normalizing telehealth and home testing, pressuring traditional pharmacies to digitize, and sparking mergers (e.g., overcoming CCI scrutiny on Medlife deal), though critics question its "unified healthtech" narrative amid competition.[5]
PharmEasy's next phase hinges on profitability post-IPO delay, leveraging Thyrocare for diagnostics dominance and expanding telehealth amid India's $50B digital health market by 2030. Trends like AI-driven personalization, insurance integrations, and rural penetration via UPI will shape it, potentially evolving influence through more acquisitions or IPO retry in a stabilizing economy. From solving access in 2015, it could redefine affordable care for India's 1.4B, if it navigates regulations and rivals effectively.[2][5]
PharmEasy has raised $323.0M across 5 funding rounds. Most recently, it raised $220.0M Series D in November 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2019 | $220.0M Series D | Bessemer Venture Partners, Fundamentum, Prime Venture Partners | |
| Sep 1, 2018 | $50.0M Series C | Bessemer Venture Partners, Fundamentum, Prime Venture Partners | |
| Feb 1, 2018 | $30.0M Series C | Bessemer Venture Partners | |
| Mar 1, 2017 | $18.0M Series B | Bessemer Venture Partners | |
| Feb 1, 2016 | $5.0M Series A | Bessemer Venture Partners |
